What question did this study set out to answer?

To evaluate the long-term adherence, tolerability, and discontinuation rates of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention in adults.

August 31, 2025CureusOpen Access

Patient Adherence and Long-Term Tolerability of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention: A Systematic Review

View Full Paper

Ask AI

Bookmark

Authors

RRRubela Ray GVGhazala S. Virk NRNishchal Regmi

Discussion

Member takes

Overview

Systematic review reveals superior adherence and sustained tolerability for anti-CGRP monoclonal antibodies in adults with migraine, indicating clear advantages over traditional oral preventives.

Key Points

To evaluate the long-term adherence, tolerability, and discontinuation rates of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention in adults.
Conducted a systematic review following PRISMA guidelines searching PubMed, Embase, CENTRAL, Scopus, and Web of Science between 2018 and 2024.
Identified 11 randomized controlled trials, real-world studies, and systematic reviews encompassing over 50,000 adult patients with episodic or chronic migraine.
Pooled 12-month adherence was approximately 55% for anti-CGRP monoclonal antibodies compared to roughly 35% for oral preventive medications.
Discontinuation due to adverse events ranged from 5.9% to 20%, driven primarily by constipation and injection-site reactions (relative risk, 1.32–1.55), while serious adverse events remained below 5%.
Responder rates achieving at least a 50% reduction in monthly migraine days increased from 44% at 3 months to 64% at 12 months, indicating favorable comparative efficacy over topiramate and onabotulinumtoxinA.

Cite This Study

Ray et al. (2025) studied this question.

synapsesocial.com/papers/69dff62e2833447a7e255754 https://doi.org/10.7759/cureus.91347

View Full Paper

Ask AI

Bookmark

August 31, 2025CureusOpen Access

Patient Adherence and Long-Term Tolerability of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention: A Systematic Review

View Full Paper

Ask AI

Bookmark

Authors

RRRubela Ray GVGhazala S. Virk NRNishchal Regmi

Discussion

Member takes

Overview

Systematic review reveals superior adherence and sustained tolerability for anti-CGRP monoclonal antibodies in adults with migraine, indicating clear advantages over traditional oral preventives.

Key Points

To evaluate the long-term adherence, tolerability, and discontinuation rates of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention in adults.
Conducted a systematic review following PRISMA guidelines searching PubMed, Embase, CENTRAL, Scopus, and Web of Science between 2018 and 2024.
Identified 11 randomized controlled trials, real-world studies, and systematic reviews encompassing over 50,000 adult patients with episodic or chronic migraine.
Pooled 12-month adherence was approximately 55% for anti-CGRP monoclonal antibodies compared to roughly 35% for oral preventive medications.
Discontinuation due to adverse events ranged from 5.9% to 20%, driven primarily by constipation and injection-site reactions (relative risk, 1.32–1.55), while serious adverse events remained below 5%.
Responder rates achieving at least a 50% reduction in monthly migraine days increased from 44% at 3 months to 64% at 12 months, indicating favorable comparative efficacy over topiramate and onabotulinumtoxinA.

Cite This Study

Ray et al. (2025) studied this question.

synapsesocial.com/papers/69dff62e2833447a7e255754 https://doi.org/10.7759/cureus.91347

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark